Nektar Therapeutics Form 4 insider transactions

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold shares to cover tax obligations related to RSU vesting and acquired new stock options.

Nektar Therapeutics' Chief Legal Officer, Mark Wilson, sold shares to cover tax obligations related to RSU vesting and saw 21,666 stock options vest.

Nektar Therapeutics' President & CEO, Howard W. Robin, sold 1,573 shares to cover tax obligations related to RSU vesting, while 86,666 stock options vested following performance target achievement.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 10,712 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Mark Andrew Wilson, Chief Legal Officer of Nektar Therapeutics, sold 9,996 shares of common stock on May 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Nektar Therapeutics CEO Howard W. Robin sold 23,208 shares of common stock on May 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 10,300 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Mark Wilson, Chief Legal Officer of Nektar Therapeutics, sold 11,040 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Nektar Therapeutics CEO Howard W. Robin sold 23,774 shares of common stock on February 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Nektar Therapeutics' Chief Legal Officer, Mark Andrew Wilson, sold a total of 49,962 shares of common stock to cover tax obligations related to vesting restricted stock units.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 51,115 shares of common stock to cover tax obligations related to vesting RSUs.

Nektar Therapeutics CEO, Howard W. Robin, sold a total of 132,030 shares of common stock to cover tax obligations related to vesting RSUs.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, acquired 135,000 shares of common stock and options for 645,000 shares through the vesting of restricted stock units and stock options.

Nektar Therapeutics' Chief Legal Officer, Mark Andrew Wilson, acquired 165,938 shares of common stock and stock options for 656,875 shares through the vesting of restricted stock units and stock options.

Nektar Therapeutics CEO Howard W. Robin acquired shares and stock options through the vesting of restricted stock units and performance-based options.

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 7,785 shares of common stock to cover tax obligations related to vesting RSUs.

Nektar Therapeutics' Chief Legal Officer, Mark Andrew Wilson, sold 6,407 shares of common stock to cover tax obligations related to vesting RSUs.

Nektar Therapeutics CEO, Howard W. Robin, sold 16,278 shares of common stock to cover tax obligations related to vesting of restricted stock units.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 6,866 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting RSUs.

Mark Andrew Wilson, Chief Legal Officer of Nektar Therapeutics, sold 5,651 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting RSUs.

Nektar Therapeutics CEO Howard W. Robin sold 14,881 shares of common stock on August 19, 2024, to cover tax withholding obligations related to vesting RSUs.

Robert Chess, a director at Nektar Therapeutics, sold 19,500 shares of common stock at an average price of $1.20 under a pre-arranged Rule 10b5-1 trading plan.

Nektar Therapeutics CEO Howard W. Robin sold 16,650 shares of common stock on May 17, 2024, to cover tax withholding obligations related to vesting RSUs.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 7,355 shares of common stock on May 17, 2024, to cover tax withholding obligations related to vesting RSUs.

Mark A. Wilson, Chief Legal Officer of Nektar Therapeutics, sold 6,260 shares of common stock on May 17, 2024, to cover tax withholding obligations related to vesting RSUs.

Deep Track Capital, a significant shareholder in Nektar Therapeutics, recently sold 56,000 shares of common stock at an average price of $1.7791.